Simultaneous Determination of Cefixime, Cefdinir and Clavulanic Acid by High Performance Liquid Chromatography
In this study, two cephalosporin groups of antibiotics (cefepime and cefixime) and their combinations with clavulanic acid, beta lactamase inhibitor, were simultaneously analyzed by HPLC method. The optimum separation was carried out on MZ $ C_{18} $ column (250 × 4.6 mm; i.d. 5 μm) with mobile phase consisting of an acetonitrile – 0.01% phosphoric acid (pH 2.5) (15 : 85, v/v) binary mixture. Detection was performed using a diode array detector at 228 nm. Under these experimental conditions, the analysis was accomplished in about 10 min. The developed method is specific, linear, sensitive, accurate, precise, and robust. The method was completely validated showing satisfactory data for all the parameters tested. Finally, the proposed method was successfully applied to two combined pharmaceutical dosage forms containing cefepime with clavulanic acid and cefixime with clavulanic acid..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Pharmaceutical chemistry journal - 54(2021), 11 vom: Feb., Seite 1186-1191 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reçber, Tuba [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| doi: |
10.1007/s11094-021-02341-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043103197 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043103197 | ||
| 003 | DE-627 | ||
| 005 | 20230519195525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210210s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11094-021-02341-z |2 doi | |
| 035 | |a (DE-627)SPR043103197 | ||
| 035 | |a (DE-599)SPRs11094-021-02341-z-e | ||
| 035 | |a (SPR)s11094-021-02341-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Reçber, Tuba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Simultaneous Determination of Cefixime, Cefdinir and Clavulanic Acid by High Performance Liquid Chromatography |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In this study, two cephalosporin groups of antibiotics (cefepime and cefixime) and their combinations with clavulanic acid, beta lactamase inhibitor, were simultaneously analyzed by HPLC method. The optimum separation was carried out on MZ $ C_{18} $ column (250 × 4.6 mm; i.d. 5 μm) with mobile phase consisting of an acetonitrile – 0.01% phosphoric acid (pH 2.5) (15 : 85, v/v) binary mixture. Detection was performed using a diode array detector at 228 nm. Under these experimental conditions, the analysis was accomplished in about 10 min. The developed method is specific, linear, sensitive, accurate, precise, and robust. The method was completely validated showing satisfactory data for all the parameters tested. Finally, the proposed method was successfully applied to two combined pharmaceutical dosage forms containing cefepime with clavulanic acid and cefixime with clavulanic acid. | ||
| 700 | 1 | |a Özkan, Ece |e verfasserin |4 aut | |
| 700 | 1 | |a Nemutlu, Emirhan |e verfasserin |4 aut | |
| 700 | 1 | |a Kır, Sedef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical chemistry journal |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1967 |g 54(2021), 11 vom: Feb., Seite 1186-1191 |w (DE-627)SPR016524810 |w (DE-600)2039418-4 |x 1573-9031 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g number:11 |g month:02 |g pages:1186-1191 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11094-021-02341-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |e 11 |c 02 |h 1186-1191 | ||